Detalles de la búsqueda
1.
Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin.
Eur J Nucl Med Mol Imaging
; 50(1): 48-60, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36001116
2.
Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington's disease.
Eur J Nucl Med Mol Imaging
; 49(4): 1166-1175, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34651228
3.
Modelling the Human Blood-Brain Barrier in Huntington Disease.
Int J Mol Sci
; 23(14)2022 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35887162
4.
Kynurenine 3-Monooxygenase Inhibition during Acute Simian Immunodeficiency Virus Infection Lowers PD-1 Expression and Improves Post-Combination Antiretroviral Therapy CD4+ T Cell Counts and Body Weight.
J Immunol
; 203(4): 899-910, 2019 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31285277
5.
Pharmacokinetics and metabolic disposition of a potent and selective kynurenine monooxygenase inhibitor, CHDI-340246, in laboratory animals.
Xenobiotica
; 51(10): 1155-1180, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34496722
6.
Application of an in Vitro Blood-Brain Barrier Model in the Selection of Experimental Drug Candidates for the Treatment of Huntington's Disease.
Mol Pharm
; 16(5): 2069-2082, 2019 05 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30916978
7.
Validation of LC-MS/MS methods for quantitative analysis of kynurenine pathway metabolites in human plasma and cerebrospinal fluid.
Bioanalysis
; 15(11): 637-651, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37170582
8.
In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using 11C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease.
J Nucl Med
; 64(10): 1581-1587, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37591545
9.
Design and Evaluation of [18F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin Aggregates.
J Med Chem
; 66(1): 641-656, 2023 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36548390
10.
Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's Disease.
J Med Chem
; 66(18): 13205-13246, 2023 Sep 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37712656
11.
Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
Sci Transl Med
; 14(630): eabm3682, 2022 02 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35108063
12.
Benefits of global mutant huntingtin lowering diminish over time in a Huntington's disease mouse model.
JCI Insight
; 7(20)2022 10 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36278490
13.
Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates.
Sci Rep
; 11(1): 17977, 2021 09 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34504195
14.
[11C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins.
J Med Chem
; 64(16): 12003-12021, 2021 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34351166
15.
Establishment of an in Vitro Human Blood-Brain Barrier Model Derived from Induced Pluripotent Stem Cells and Comparison to a Porcine Cell-Based System.
Cells
; 9(4)2020 04 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32316221
16.
Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand.
J Med Chem
; 63(15): 8608-8633, 2020 08 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32662649
17.
The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
Exp Neurol
; 282: 99-118, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27163548
Resultados
1 -
17
de 17
1
Próxima >
>>